Trimethylamine N-oxide (TMAO), a gut microbiota-host co-metabolite, associates with fewer internalizing behavioral problems in a cross-sectional cohort of 1,203 children, while its microbial precursor trimethylamine (TMA) associates with more behavioral problems — a divergence confirmed in an independent longitudinal study tracking 630–820 children from ages 1 to 15. Critically, TMAO modified the neurodevelopmental harm linked to arsenic exposure and, in a human neuronal-astrocyte co-culture model, activated synaptogenesis-related gene expression and protected against mercury-induced neuronal damage.
These findings reframe TMAO's contested reputation in health science. Cardiovascular research has long positioned elevated TMAO as a risk factor for atherosclerosis and adverse cardiac events, yet this work — consistent with earlier murine data showing blood-brain barrier benefits — suggests tissue-specific and context-dependent protective roles, particularly in neural development. The TMA-versus-TMAO divergence is mechanistically intriguing: the same microbial pathway produces both a potentially harmful precursor and a seemingly neuroprotective oxidized product, raising questions about host flavin-containing monooxygenase (FMO3) activity as a modifier of neurodevelopmental risk. Practical implications remain premature; TMAO is diet-derived primarily from red meat and fish, making targeted supplementation complicated by cardiovascular trade-offs. Limitations include observational epidemiology susceptible to confounding, in vitro-to-human translation gaps, and moderate cohort sizes. As a preprint not yet peer-reviewed, these results require independent replication and methodological scrutiny before influencing clinical or dietary guidance.